# Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease

> **NCT00806676** · NA · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 67 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Gardasil® Vaccine (FDA-approved vaccination regimen)

## Key facts

- **NCT ID:** NCT00806676
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2017-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00806676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00806676, "Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00806676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*